Results 51 to 60 of about 158,005 (297)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Innovative lipid-lowering therapy: experience of inclisiran use in the Republic of Belarus

Российский кардиологический журнал, 2023
The article reflects modern aspects of lipid-lowering therapy, based on the as­sessment of cardiovascular risk, and the possibilities of triple therapy, including statins, ezetimibe, and inclisiran.We present our own data on the use of the drug ...
E. A. Medvedeva, E. A. Grigorenko, N. P. Mitkovskaya   +2 more
doaj   +1 more source

Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council

Рациональная фармакотерапия в кардиологии, 2021
The meeting of the expert council of cardiologists-lipidologists, organized with the support of Novartis and dedicated to the discussion of the existing system of medical care for patients with familial hypercholesterolemia / mixed dyslipidemia, the ...
M. V. Ezhov, V. V. Kukharchuk, I. V. Sergienko, N. M. Akhmedzhanov, M. I. Voevoda, V. S. Gurevich, V. V. Kashtalap, V. O. Konstantinov, V. V. Skibitsky, I. I. Shaposhnik   +9 more
doaj   +1 more source

Lipid lowering therapy.

, 2013
Lipid lowering therapy.
Zhi Jian Wang (400794), Xiao Li Liu (400795), Yu Jie Zhou (400790), Fei Gao (29262), Shi Wei Yang (137758), Da Yi Hu (400791), Ying Xin Zhao (400792), Yu Yang Liu (400793)   +7 more
core   +1 more source

Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice

FEBS Open Bio, EarlyView.
Erythropoietin administration suppresses hepatic soluble epoxide hydrolase (sEH) expression, leading to increased CYP‐derived epoxides. This is associated with a shift in hepatic macrophage polarization characterized by reduced M1 markers and increased M2 markers, along with reduced hepatic inflammation, suppressed hepatic lipogenesis, and attenuated ...
Takeshi Goda, Satoru Sugimoto, Chiharu Cho, Madoka Konishi, Nozomi Inoue, Satoshi Miyagaki, Yasuhiro Kawabe, Takuro Okamura, Masahide Hamaguchi, Hisakazu Nakajima, Michiaki Fukui, Masakazu Shinohara, Tomoko Iehara   +12 more
wiley   +1 more source

Use of lipid-lowering therapy.

, 2015
aNon-statin LLT: ezetimibe, fibrates, nicotinic acid, anion exchange resins.LLT, lipid-lowering therapy; SCORE, Systematic Coronary Risk Evaluation.Use of lipid-lowering therapy.
José R. Banegas (318601), Joep Perk (693176), Julian P. Halcox (693173), Claudio Borghi (654027), Esther Lopez-Garcia (5068805), Ogün Sazova (693177), Fernando Rodriguez-Artalejo (4657693), Guy De Backer (693174), Jean Dallongeville (224373), Eliseo Guallar (27363), Jesús Medina (693175), Carine Roy (84997), Stephen Sweet (693178), Florence Tubach (77841)   +13 more
core   +1 more source

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

FEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar, Francesco Michelangeli, Farhat Latif Khanim, Christopher Martin Bunce, William Eustace Basil Johnson   +4 more
wiley   +1 more source

Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice

FEBS Open Bio, EarlyView.
In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue.
Jade Gauvin, Naghme Radmannia, David N. Huynh, Liliane Ménard, Caroline Daneault, Maïté Veilleux, Ahsanullah Ahsanullah, André C. Carpentier, William D. Lubell, Matthieu Ruiz, Huy Ong, Sylvie Marleau, Simon‐Pierre Gravel   +12 more
wiley   +1 more source

The era of targeted therapy for hyperlipidemia

Российский кардиологический журнал
Despite a variety of lipid-lowering drugs, mostly pelleted, aimed at reducing low-density lipoprotein cholesterol and triglycerides, only a small number of patients achieve their target levels.
U. V. Chubykina, A. V. Tyurina, M. V. Ezhov   +2 more
doaj   +1 more source

Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease

, 2011
*This article is free to read on the publisher's website*\ud \ud Background: \ud \ud Inflammation and biomechanical factors have been associated with the development of vulnerable atherosclerotic plaques.
Tang, T. Y., Tjun Y Tang, Jonathan H Gillard, Li, Z. Y., Jiang, F., Zhi-Yong Li, Fan Jiang, Gillard, J. H., Zhang, Y., Yun Zhang   +9 more
core   +1 more source